Kevin Booth

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

D. Hill, P. Scheltens, A. Gass, 2016, Alzheimer's Research & Therapy.

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

J. Pariente, R. Black, A. Ivanoiu, 2016, Alzheimer's Research & Therapy.